CINECA IRIS Institutional Research Information System

RIBALDONE, Davide Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.420
EU - Europa 7.335
AS - Asia 4.181
SA - Sud America 765
AF - Africa 241
OC - Oceania 199
Continente sconosciuto - Info sul continente non disponibili 20
Totale 27.161
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.937
IT - Italia 2.264
CN - Cina 1.791
IE - Irlanda 816
SE - Svezia 594
GB - Regno Unito 494
DE - Germania 465
FR - Francia 441
ES - Italia 416
VN - Vietnam 368
TR - Turchia 367
BR - Brasile 341
IN - India 339
JP - Giappone 336
PL - Polonia 300
UA - Ucraina 242
CA - Canada 240
MX - Messico 204
AU - Australia 163
FI - Finlandia 142
KR - Corea 142
AT - Austria 138
CO - Colombia 137
NL - Olanda 137
ID - Indonesia 134
HK - Hong Kong 127
RU - Federazione Russa 116
BE - Belgio 104
CH - Svizzera 99
CL - Cile 93
IR - Iran 93
SG - Singapore 93
PT - Portogallo 88
RO - Romania 85
PE - Perù 83
EG - Egitto 82
GR - Grecia 76
TW - Taiwan 76
AR - Argentina 61
CZ - Repubblica Ceca 58
HU - Ungheria 55
DK - Danimarca 50
IL - Israele 49
TH - Thailandia 43
NZ - Nuova Zelanda 35
SA - Arabia Saudita 35
PK - Pakistan 34
PH - Filippine 29
EC - Ecuador 24
HR - Croazia 23
MY - Malesia 23
NO - Norvegia 23
TN - Tunisia 21
KE - Kenya 20
NG - Nigeria 20
SI - Slovenia 19
ZA - Sudafrica 18
ET - Etiopia 16
EU - Europa 16
PA - Panama 16
BG - Bulgaria 15
IQ - Iraq 15
VE - Venezuela 15
GH - Ghana 13
LT - Lituania 13
MA - Marocco 13
BD - Bangladesh 12
RS - Serbia 11
AE - Emirati Arabi Uniti 10
JO - Giordania 10
SN - Senegal 10
EE - Estonia 9
SK - Slovacchia (Repubblica Slovacca) 9
UZ - Uzbekistan 9
DZ - Algeria 8
UY - Uruguay 8
BA - Bosnia-Erzegovina 7
KW - Kuwait 7
KZ - Kazakistan 6
LV - Lettonia 6
AF - Afghanistan, Repubblica islamica di 5
AL - Albania 4
AP - ???statistics.table.value.countryCode.AP??? 4
CU - Cuba 4
DO - Repubblica Dominicana 4
HN - Honduras 4
LB - Libano 4
PS - Palestinian Territory 4
SD - Sudan 4
BY - Bielorussia 3
CR - Costa Rica 3
GE - Georgia 3
GT - Guatemala 3
LU - Lussemburgo 3
MO - Macao, regione amministrativa speciale della Cina 3
NP - Nepal 3
QA - Qatar 3
TZ - Tanzania 3
BO - Bolivia 2
IS - Islanda 2
Totale 27.125
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.872
Chandler 1.532
Fairfield 1.072
Dublin 802
Ashburn 701
Beijing 598
Redwood City 565
Houston 532
Torino 524
Woodbridge 444
Seattle 401
Wilmington 397
Jacksonville 394
Cambridge 346
Nyköping 241
Dong Ket 237
Princeton 212
Medford 209
Pisa 201
Turin 196
Villeurbanne 172
Dearborn 145
Warsaw 144
Shanghai 136
Milan 128
Nanjing 113
Vienna 103
Boston 101
Rome 99
Guangzhou 96
Hangzhou 94
Istanbul 94
San Diego 92
New York 81
London 74
Tokyo 70
Seoul 69
Helsinki 58
Santiago 58
Lima 57
Duncan 56
Bogotá 52
Ottawa 52
Barcelona 51
Wuhan 51
Brussels 49
Madrid 48
Chengdu 47
Washington 46
Ankara 45
Fremont 45
Upper Marlboro 45
Boardman 43
Singapore 43
Toronto 43
Berlin 42
Zhengzhou 42
Norwalk 40
Medellín 38
São Paulo 36
Hebei 35
Hyderabad 35
Bengaluru 32
Buenos Aires 32
Jakarta 32
Bologna 30
Hefei 30
Central District 29
Paris 29
Taipei 29
Amsterdam 28
Central 28
Chicago 28
Los Angeles 28
Cairo 27
Jinan 27
Silver Spring 26
Tainan City 25
Tehran 25
Moscow 24
Athens 23
Changsha 22
Indore 22
Izmir 22
Bangkok 21
Kunming 21
Naples 21
Hong Kong 20
Phoenix 20
Prague 20
Budapest 19
Melbourne 19
Polska 19
San Mateo 19
Fuzhou 18
Guadalajara 18
Lappeenranta 18
Padova 18
Bucharest 17
Linköping 17
Totale 16.347
Salva come PNG Salva come JPEG
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.606
Risk of drug interactions and prescription appropriateness in elderly patients 1.004
Proctitis: a glance beyond inflammatory bowel diseases 879
Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response 598
Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series 536
The gut and the Inflammatory Bowel Diseases inside-out: the extra-intestinal manifestations 445
Eosinophilic colitis: clinical review and 2020 update 425
ACG Clinical Guideline on Crohn’s Disease: A Point of View from Europe 405
A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms 400
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets 319
Management of Helicobacter pylori in Piedmont, Italy 292
Fecal calprotectin: beyond intestinal organic diseases 279
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 270
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study 269
Adalimumab trough levels predict Crohn's disease clinical course 260
Differential diagnosis of pancreatic cysts: A prospective study on the role of intra-cystic glucose concentration 254
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients 241
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 234
Gut microbiota and chronic exercise in diabetic patients: not only bacteria 233
Biosimilar CT-P13 in treating ulcerative colitis in the real world 228
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 222
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy 214
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis 206
Physiopathology of intestinal barrier and the role of zonulin 204
Prevalence of infectious agents in patients with systemic sclerosis: Defining the control group 196
Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience 192
Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score 190
Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? 188
Bone mineral density at diagnosis of celiac disease and after 1 year of gluten-free diet 180
The therapy of chronic pouchitis 180
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease? 176
Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators 174
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index 173
Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message 172
Is there a link between periampullary diverticula and biliopancreatic disease? An EUS approach to answer the question 171
Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series 170
Food supplements, stress and gastrointestinal diseases 168
AMOXYCILLIN AND METRONIDAZOLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A 10-YEAR TREND IN TURIN, ITALY 165
2013 update on celiac disease and eosinophilic esophagitis 160
Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? 160
Bariatric Surgery and Inflammatory Bowel Disease: a Role for Microbiota? 158
Adnexal localization of crohn’s disease and recurrent massive ovary cysts 149
Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? 147
Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp" 145
Does Helicobacter pylori infection increase the risk of adult-onset asthma? 143
Periodontal health and coronary heart disease: a comment 143
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 143
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study 143
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 138
Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test 137
Comments on Sulimani et al.: A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females 136
Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease 134
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis 133
Efficacy of infliximab biosimilars in patients with Crohn's disease 133
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 132
Real time visualization may be advisable to exclude aspiration in patients undergoing capsule endoscopy examination 132
Helicobacter pyloriinfection and asthma: Is there a direct or an inverse association? A meta-analysis 131
Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video) 131
Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough? 131
OC. 12.4 PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE: ANALYSIS OF INTESTINAL OUTCOME AFTER LIVER TRANSPLANTATION 130
On Inverse Association between Helicobacter pylori Gastritis and Microscopic Colitis: The European Data 129
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 129
Response to: Comment on "efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients" 128
Is Helicobacter pylori the infectious trigger for headache?: A review 128
Power Doppler sonography to predict the risk of surgical recurrence of Crohn’s disease 126
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis 126
Helicobacter pylori eradication: poor medical compliance from East to West of the world 125
A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms 125
How ameliorate the adherence in patients with inflammatory bowel disease? 124
V.02.10 AN INNOVATIVE EVALUATION OF PANCREATIC CYSTS BY CONFOCAL LASER ENDOMICROSCOPY AND FIBER OPTIC LIGHTING DIRECT VISUALIZATION SYSTEM 123
Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment 123
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians 122
Inflammation in gastrointestinal disorders: prevalent socioeconomic factors 121
Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis 121
How to interpret meta-analysis results 119
AISF position paper on HCV in immunocompromised patients 118
Mo1920 – Results of Interim Analysis of a Retrospective Igibd Study on Adalimumab Use in Real Practice in Italy: the Real-Life Clinical Effectiveness of Adalimumab in Ulcerative Colitis (REALADA-UC) Study 118
Mo1867 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE 118
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease? 118
Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study 117
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 117
P02.38 | Current practice of Gastroenterologists in the treatment of Helicobacter pylori infection in Italy: data from the Italian Registry on H. pylori treatment 116
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease 116
Features of inflammatory bowel disease followed in a second level center in Northern Italy 115
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 112
Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study" 111
Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study 110
Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity 110
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 108
Benefit of supplements in functional dyspepsia after treatment of Helicobacter pylori 107
Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma 107
IS THERE A LINK BETWEEN PERIAMPULLARY DIVERTICULA AND BILIOPANCREATIC DISEASES? AN EUS APPROACH TO ANSWER THE QUESTION 106
Helicobacter pylori prevalence: Are the data totally reliable? 106
Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients 106
COVID-19: a user's guide, status of the art and an original proposal to terminate viral recurrence 104
P402 Interstitial and granulomatous lung disease in inflammatory bowel disease patients 104
THE ROLE OF ANTI-IFI16 ANTIBODIES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD) 103
Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 103
The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm 103
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 103
Totale 20.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.252
article - articoli 0
book - libri 0
conference - conferenze 4.430
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.682
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019609 0 0 0 0 0 0 0 0 0 135 345 129
2019/20203.313 138 113 67 298 133 268 308 423 462 422 276 405
2020/20214.931 275 435 407 346 379 455 364 300 405 441 408 716
2021/20227.212 377 297 317 374 319 367 1.364 1.170 915 371 699 642
2022/20236.378 499 457 319 518 620 1.131 599 464 738 296 429 308
2023/20243.641 440 504 294 384 463 495 283 467 87 224 0 0
Totale 28.208